J Marie Suga
Hematology & Oncology · Vallejo, CANPI 1972710119
Payments from drug & device makers
Across 751 payments — averaging $9127.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Genentech, Inc.$2.1M
- Seagen Inc.$1.3M
- Merck$753K
- F. Hoffmann-la Roche AG$560K
- Pfizer$463K
- Eli Lilly$429K
- plus $1.3M from 12 others
Across 3 payments — averaging $2885.97 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$9K
- Seagen Inc.$65
What the payments were for
- Food & beverage$447100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Genentech, Inc. | 347 | $2,062,317 |
| Seagen Inc. | 115 | $1,308,008 |
| Merck | 38 | $753,016 |
| F. Hoffmann-la Roche AG | 98 | $560,229 |
| Pfizer | 28 | $463,272 |
| Eli Lilly | 28 | $428,708 |
| E.r. Squibb & Sons, L.L.C. | 36 | $405,937 |
| Puma Biotechnology, Inc. | 17 | $312,152 |
| Daiichi Sankyo Inc. | 9 | $159,686 |
| AstraZeneca | 1 | $159,139 |
| Mirati Therapeutics, Inc. | 9 | $102,702 |
| Astellas Pharma Global Development | 2 | $46,000 |
| Beone Medicines USA, Inc. | 3 | $41,246 |
| GSK | 13 | $31,896 |
| Macrogenics, Inc. | 4 | $19,746 |
| Janssen Research & Development, LLC | 1 | $150 |
| Astrazeneca UK Limited | 1 | $135 |
| Genentech USA, Inc. | 1 | $77 |
How this compares
$6,854,417 in reported general payments places this provider in the 95th percentile of 1,363 hematology & oncology providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TagrissoOsimertinib Mesylate | 88 | $1,488,073 |
| BrukinsaZanubrutinib | 29 | $381,499 |
| XtandiEnzalutamide | 27 | $328,344 |
| VerzenioAbemaciclib | 15 | $238,633 |
| IbrancePalbociclib | 14 | $218,962 |
| InlytaAxitinib | 11 | $175,114 |
| Lenalidomide | 14 | $170,236 |
| GilotrifAfatinib Dimaleate | 11 | $141,438 |
| BraftoviEncorafenib | 11 | $108,883 |
| NivestymFilgrastim-Aafi | 22 | $14,087 |
| Anastrozole | 46 | $1,294 |
| Hydroxyurea | 19 | $805 |
| Imatinib Mesylate | 11 | $786 |
| ComproProchlorperazine | 13 | $671 |
| Tamoxifen Citrate | 24 | $631 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaTagrisso | $159,139 | $1,488,07388 claims |
| PfizerIbrance, Inlyta, Nivestym | $463,272 | $408,16247 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,363 hematology & oncology providers in California.
Other hematology & oncology in Vallejo
- Alain AlgaziSan Francisco$119.2M
- David BerzLos Angeles$43.3M
- Jonathan GoldmanSanta Monica$35.7M
- Omid HamidSanta Monica$23.7M
- Nicholas McAndrewLos Angeles$22.9M
- Aditya BardiaSanta Monica$22.1M
- Joseph TuscanoSacramento$20.4M
- Zev WainbergSanta Monica$19.3M
- Caitlin CostelloSan Diego$16.9M
- Rana McKaySan Diego$15.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.